BIOXYNE ORD
Bioxyne Boosts FY26 Outlook on Strong Performance and International Growth
Bioxyne lifts FY26 EBITDA guidance to AUD16.5-19m after record H1 FY2026 with AUD31.3m revenue (+149% YoY); expands capacity, enters UK/Germany/LATAM.
Bioxyne Receives $1.7m Funding from Scottish Government Agency for UK Medicinal Cannabis Manufacturing Facility
Bioxyne (ASX: BXN) subsidiary Breathe Life Sciences UK has received approximately $1.7 million in funding from economic development agency South of Scotland Enterprise (SOSE) to establish its UK medicinal cannabis manufacturing and distribution facility.
Bioxyne earns international GMP certification, strikes $5.6m German API supply deal
Bioxyne (ASX: BXN) has received certificates of Good Manufacturing Practice (GMP) compliance under mutual recognition agreements with five countries. The company’s wholly owned subsidiary Breathe Life Sciences – a GMP-licensed manufacturer, wholesaler, importer and exporter of controlled substances including medicinal cannabis, psilocybin and MDMA – earned the certification. Agreements with Singapore, the European Union, Canada, […]
Bioxyne upgrades FY25 outlook by $3m to $28m on rising demand for psychedelic drug therapies
Diversified health products company Bioxyne (ASX: BXN) has upgraded its full-year revenue guidance for financial year 2025 by $3 million to $28m. The upgrade follows reported revenue of $12.6m for the first six months of the year, which represents a 267% increase on the previous corresponding period (pcp). Bioxyne is forecasting revenue of $15.4m for […]